Solid Tumors Clinical Trial
Official title:
A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS [R], ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
Background:
- Trabectedin is an experimental drug that kills some cancer cells in the laboratory and
in mice by interfering with genetic material (DNA) in cancer cells.
- In some adult patients with cancer who received trabectedin, tumors grew slower or
shrank.
Objectives:
- To determine a dose of trabectedin that can be given safely to children and adolescents
as a 24-hour continuous infusion through a vein.
- To determine the side effects of trabectedin in children and adolescents.
- To study how the body handles trabectedin by measuring the amount of the drug in the
bloodstream over time after a dose is given.
- To measure the effect of trabectedin on DNA in white blood cells.
- To determine if an individual's tumor cells have a specific proteins involved in DNA
repair and if a pattern of genes can be identified in tumor samples that might help
explain why trabectedin reduces tumors in some individuals and not others.
- To study genetic factors that may influence the way the body handles trabectedin.
- To see if trabectedin is beneficial in certain types of cancer.
Eligibility:
-Children between 4 year and 17 years of age with tumors that recur or no longer respond to
standard treatment.
Design:
- Patients receive trabectedin as a 24-hour continuous infusion repeated every 21 days.
The first three children entering the study receive a dose of 1.1 mg/m2. Subsequent
groups of up to six patients receive higher doses (1.5 mg/m2 and 1.7 mg/m2) as long as
the preceding dose is well tolerated. Patients enrolled at the lowest dose level may
have their dose increased to the next level if they tolerated the lower dose well.
Treatment may continue as long as the cancer does not worsen and the treatment is
tolerated.
- Patients have blood drawn on days 1, 2, 3, 4, 5 and 7 of the first treatment cycle to
study how the body handles trabectedin.
- A tumor sample obtained from a prior surgery or biopsy is examined for proteins involved
in DNA repair.
- A blood sample is drawn to look for genetic factors that may influence how the body
handles trabectedin.
- Patients have periodic physical examinations and blood tests. MRI or CT scans are done
before starting therapy and after every two treatment cycles to evaluate the tumor.
Background:
Trabectedin (ET-743) is a natural product derived from the marine tunicate Ecteinascidia
turbinata. It binds to the minor groove of DNA and interacts with various transcription
factors resulting in cell cycle arrest. It also inhibits transcription coupled nucleotide
excision repair system inducing lethal DNA strand breaks.
In preclinical and clinical studies, trabectedin has been found to be active in many soft
tissue sarcomas including leiomyosarcoma, synovial cell sarcoma, neuroblastoma,
rhabdomyosarcoma, melanoma, breast, ovarian, non-small cell lung, renal and prostate
carcinoma.
In adult phase I and phase II studies, trabectedin has been well-tolerated up to dose levels
of 1.9mg/m(2)/dose with the most common toxicities being fatigue, neutropenia, and reversible
transaminase elevations. Objective responses were seen at doses equal to or greater than
1.5mg/m(2)/dose. Trabectedin 1.5mg/m(2) administered as a 24-hour continuous intravenous
infusion is the recommended dose and schedule in adults.
A pediatric phase I study of trabectedin administered as a 3-hour infusion has been completed
in the Children's Oncology Group. The maximum tolerated dose was 1.1 mg/m(2). Dose limiting
toxicity was reversible elevation of hepatic transaminases.
Objectives:
Determine the maximum tolerated dose (MTD) of trabectedin administered as a 24-hour
continuous infusion in children and adolescents with relapsed or refractory solid tumors.
Define the toxicity profile of trabectedin administered as a 24-hr infusion in children and
adolescents.
Describe the pharmacokinetics of trabectedin administered as a 24-hr infusion in children and
adolescents.
Quantify double strand DNA breaks in peripheral blood mononuclear cells of patients receiving
trabectedin.
Evaluate archival formalin fixed paraffin embedded tumor tissue, when available from prior
biopsies or surgical procedures, for the expression of the nucleotide excision repair
proteins and genomic instability markers (histone gamma-H2AX, phospho-ATM, phospho-Chk2) by
immunohistochemistry
Molecular characterization of DNA repair genes and correlation to outcome using mRNA isolated
from microdissected archival formalin fixed, paraffin embedded tumor sections.
Study the pharmacogenetics of host DNA repair proteins and drug metabolizing enzymes to
explore the impact of host factors on trabectedin toxicity.
Eligibility:
Children greater than or equal to 4 years and less than 17 years of age with relapsed or
refractory solid tumors.
Design:
Patients will receive trabectedin as a 24-hour continuous infusion repeated every 21 days.
The starting dose level is 1.1mg/m(2)/dose with escalations to 1.5mg/m(2)/dose and
1.7mg/m(2)/dose.
All patients will receive dexamethasone pretreatment and growth factor support with
filgrastim or pegfilgrastim.
The definition of dose-limiting hepatic toxicity will be identical to the definition used in
phase I trials in adults on the same dosing schedule.
Pharmacokinetic analysis will be performed on days 1, 2, 3, 4, 5 and 7 of the first treatment
cycle.
Three to six patients will be enrolled at the first dose level and up to 6 patients will be
enrolled on subsequent dose levels. Dose escalation will be based on tolerability of
trabectedin at the prior dose level. For patients enrolled at dose level 1 (1.1mg/m(2)),
intrapatient dose escalation to dose level 2 (1.5mg/m(2)) will be allowed with subsequent
cycles if no dose limiting toxicities occurred at the lower dose level. Total accrual will be
up to 24 patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |